Switch theme
Sign up to access all valuation multiples
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
2009
n/a
LTM Revenue $199M
LTM EBITDA $47.1M
$841M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chengdu Easton has a last 12-month revenue (LTM) of $199M and a last 12-month EBITDA of $47.1M.
In the most recent fiscal year, Chengdu Easton achieved revenue of $187M and an EBITDA of $47.1M.
Chengdu Easton expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chengdu Easton valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $199M | XXX | $187M | XXX | XXX | XXX |
| Gross Profit | $149M | XXX | $140M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $47.1M | XXX | $47.1M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBIT | $37.4M | XXX | $30.8M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $35.2M | XXX | $33.1M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | 18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chengdu Easton's stock price is CNY 42 (or $6).
Chengdu Easton has current market cap of CNY 7.4B (or $1.0B), and EV of CNY 6.1B (or $841M).
See Chengdu Easton trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $841M | $1.0B | XXX | XXX | XXX | XXX | $0.20 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chengdu Easton has market cap of $1.0B and EV of $841M.
Chengdu Easton's trades at 4.5x EV/Revenue multiple, and 17.9x EV/EBITDA.
Equity research analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chengdu Easton has a P/E ratio of 29.2x.
See valuation multiples for Chengdu Easton and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $841M | XXX | $841M | XXX | XXX | XXX |
| EV/Revenue | 4.2x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBITDA | 17.8x | XXX | 17.9x | XXX | XXX | XXX |
| EV/EBIT | 22.5x | XXX | 27.3x | XXX | XXX | XXX |
| EV/Gross Profit | 5.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 29.2x | XXX | 31.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 41.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChengdu Easton's last 12 month revenue growth is 16%
Chengdu Easton's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Chengdu Easton's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chengdu Easton's rule of X is 64% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chengdu Easton and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 9% | XXX | XXX | XXX |
| Rule of 40 | 45% | XXX | 41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 64% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 28% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Easton acquired XXX companies to date.
Last acquisition by Chengdu Easton was XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Easton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chengdu Easton founded? | Chengdu Easton was founded in 2009. |
| Where is Chengdu Easton headquartered? | Chengdu Easton is headquartered in China. |
| Is Chengdu Easton publicy listed? | Yes, Chengdu Easton is a public company listed on SHG. |
| What is the stock symbol of Chengdu Easton? | Chengdu Easton trades under 688513 ticker. |
| When did Chengdu Easton go public? | Chengdu Easton went public in 2020. |
| Who are competitors of Chengdu Easton? | Similar companies to Chengdu Easton include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Chengdu Easton? | Chengdu Easton's current market cap is $1.0B |
| What is the current revenue of Chengdu Easton? | Chengdu Easton's last 12 months revenue is $199M. |
| What is the current revenue growth of Chengdu Easton? | Chengdu Easton revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Chengdu Easton? | Current revenue multiple of Chengdu Easton is 4.2x. |
| Is Chengdu Easton profitable? | Yes, Chengdu Easton is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chengdu Easton? | Chengdu Easton's last 12 months EBITDA is $47.1M. |
| What is Chengdu Easton's EBITDA margin? | Chengdu Easton's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Chengdu Easton? | Current EBITDA multiple of Chengdu Easton is 17.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
